165 related articles for article (PubMed ID: 37485727)
41. [Successful treatment of three elderly patients suffering from prolonged delirium using the cholinesterase inhibitor rivastigmine].
Kalisvaart CJ; Boelaarts L; de Jonghe JF; Hovinga IM; Kat MG
Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1501-4. PubMed ID: 15481575
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
Almaraz AC; Driver-Dunckley ED; Woodruff BK; Wellik KE; Caselli RJ; Demaerschalk BM; Adler CH; Caviness JN; Wingerchuk DM
Neurologist; 2009 Jul; 15(4):234-7. PubMed ID: 19590387
[TBL] [Abstract][Full Text] [Related]
43. Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons.
Ruggiero C; Bonamassa L; Pelini L; Prioletta I; Cianferotti L; Metozzi A; Benvenuti E; Brandi G; Guazzini A; Santoro GC; Mecocci P; Black D; Brandi ML
Osteoporos Int; 2017 Feb; 28(2):667-675. PubMed ID: 27717957
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
Tricco AC; Soobiah C; Berliner S; Ho JM; Ng CH; Ashoor HM; Chen MH; Hemmelgarn B; Straus SE
CMAJ; 2013 Nov; 185(16):1393-401. PubMed ID: 24043661
[TBL] [Abstract][Full Text] [Related]
45. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
[TBL] [Abstract][Full Text] [Related]
46. Agreement Between the Mini-Cog in the Preoperative Clinic and on the Day of Surgery and Association With Postanesthesia Care Unit Delirium: A Cohort Study of Cognitive Screening in Older Adults.
Tiwary N; Treggiari MM; Yanez ND; Kirsch JR; Tekkali P; Taylor CC; Schenning KJ
Anesth Analg; 2021 Apr; 132(4):1112-1119. PubMed ID: 33002933
[TBL] [Abstract][Full Text] [Related]
47. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
[TBL] [Abstract][Full Text] [Related]
48. Effects of rivastigmine on memory and cognition in multiple sclerosis.
Shaygannejad V; Janghorbani M; Ashtari F; Zanjani HA; Zakizade N
Can J Neurol Sci; 2008 Sep; 35(4):476-81. PubMed ID: 18973065
[TBL] [Abstract][Full Text] [Related]
49. Rivastigmine for the management of anticholinergic delirium.
Chiew AL; Holford AG; Chan BSH; Isoardi KZ
Clin Toxicol (Phila); 2024 Feb; 62(2):82-87. PubMed ID: 38465631
[TBL] [Abstract][Full Text] [Related]
50. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Modrego PJ; Pina MA; Fayed N; Díaz M
CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
[TBL] [Abstract][Full Text] [Related]
51. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Farlow MR; Hake A; Messina J; Hartman R; Veach J; Anand R
Arch Neurol; 2001 Mar; 58(3):417-22. PubMed ID: 11255445
[TBL] [Abstract][Full Text] [Related]
52. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
53. Successful treatment of nonanticholinergic delirium with a cholinesterase inhibitor.
Fischer P
J Clin Psychopharmacol; 2001 Feb; 21(1):118. PubMed ID: 11199939
[No Abstract] [Full Text] [Related]
54. Delirium in elderly hospitalised patients: protective effects of chronic rivastigmine usage.
Dautzenberg PL; Mulder LJ; Olde Rikkert MG; Wouters CJ; Loonen AJ
Int J Geriatr Psychiatry; 2004 Jul; 19(7):641-4. PubMed ID: 15254920
[TBL] [Abstract][Full Text] [Related]
55. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
[TBL] [Abstract][Full Text] [Related]
56. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
[TBL] [Abstract][Full Text] [Related]
57. Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Spalletta G; Caltagirone C; Padovani A; Sorbi S; Attar M; Colombo D; Cravello L;
PLoS One; 2014; 9(2):e89216. PubMed ID: 24586603
[TBL] [Abstract][Full Text] [Related]
58. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
[TBL] [Abstract][Full Text] [Related]
59. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Kumar V; Anand R; Messina J; Hartman R; Veach J
Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
[TBL] [Abstract][Full Text] [Related]
60. Pre-operative mild cognitive dysfunction predicts risk for post-operative delirium after elective cardiac surgery.
Veliz-Reissmüller G; Agüero Torres H; van der Linden J; Lindblom D; Eriksdotter Jönhagen M
Aging Clin Exp Res; 2007 Jun; 19(3):172-7. PubMed ID: 17607083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
